Podcasts about orexigen

  • 6PODCASTS
  • 12EPISODES
  • 13mAVG DURATION
  • ?INFREQUENT EPISODES
  • Nov 18, 2020LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about orexigen

Latest podcast episodes about orexigen

Oral Arguments for the Court of Appeals for the Third Circuit

In Re Orexigen Therapeutics

therapeutics orexigen
Oral Arguments for the Court of Appeals for the Third Circuit

In Re Orexigen Therapeutics

therapeutics orexigen
The Bio Report
Can a Direct Pitch to Patients Drive a Home Run for Obesity Drug

The Bio Report

Play Episode Listen Later Aug 31, 2017 23:43


Winning regulatory approval for a drug to treat obesity would seem like a great accomplishment, but for Orexigen Therapeutics, that's when the hard work began. After its marketing partner Takeda ended their agreement because of disappointing sales, the company found itself in the position of having to market a drug to doctors who often don't consider obesity an illness and believe willpower and discipline, not a pill, is what's needed. Orexigen's solution centered on a novel approach. The company decided to make a pitch directly to patients and connect them to telehealth-based doctors, who could ensure use of the drug is appropriate and help them avoid the embarrassment they may feel when speaking to their own doctors. We spoke to Thomas Cannell, Chief Operating Officer and President of Global Commercial Products for Orexigen, about its obesity drug Contrave, its marketing strategy, and whether it represents a marketing model that others may follow.

Empowered Patient Podcast
Motivated to Combat Hunger and Cravings with Salma Jutt Orexigen

Empowered Patient Podcast

Play Episode Listen Later Jun 7, 2017 16:18


Salma Jutt, Vice President of Marketing US, Orexigen Theraputics talks about their obesity drug CONTRAVE and how it works on two areas of the brain to reduce hunger and cravings.  This is a drug for those committed to stick to a regime of exercise and diet and can help keep the weight off.  A growing business in this age of selfies where there is an increasing interest in improving appearances and nearly unlimited opportunities to satisfy cravings for the wrong foods. CONTRAVE.com

FirstWord Pharmaceutical News
FirstWord Pharmaceutical News for Friday, June 5, 2015

FirstWord Pharmaceutical News

Play Episode Listen Later Jun 5, 2015 1:36


FirstWord Pharmaceutical News
FirstWord Pharmaceutical News for Wednesday, May 13, 2015

FirstWord Pharmaceutical News

Play Episode Listen Later May 13, 2015 1:37


Industry Focus
Healthcare: Are These Two Biotech Stocks Too Risky To Buy?​

Industry Focus

Play Episode Listen Later Mar 11, 2015 18:13


MannKind and Orexigen: two companies with big promise, but can they deliver on profit? Healthcare analyst Michael Douglass and healthcare contributor Todd Campbell discuss the risks facing these biotech stocks.

FirstWord Pharmaceutical News
FirstWord Pharmaceutical News for Wednesday, March 4, 2015

FirstWord Pharmaceutical News

Play Episode Listen Later Mar 4, 2015 1:38


FirstWord Pharmaceutical News
FirstWord Pharmaceutical News for Wednesday, September 10, 2014

FirstWord Pharmaceutical News

Play Episode Listen Later Sep 10, 2014 10:03


FirstWord Pharmaceutical News
FirstWord Pharmaceutical News for Thursday, June 12, 2014

FirstWord Pharmaceutical News

Play Episode Listen Later Jun 12, 2014 9:20


FirstWord Pharmaceutical News
FirstWord Pharmaceutical News for Tuesday, November 26, 2013

FirstWord Pharmaceutical News

Play Episode Listen Later Nov 26, 2013 10:55


Today in FirstWord:

Venture Perspectives by Scale Venture Partners
Success is in the Air for Lou Bock

Venture Perspectives by Scale Venture Partners

Play Episode Listen Later Sep 29, 2009


It’s August 2009 and in the last 12 months, Lou Bock‘s portfolio has had some impressive success. He talks about how Zogenix, Horizon Therapeutics, Somaxon, Prestwick Pharmaceuticals and Orexigen have all done well. The Scale Venture Partners Managing Director has seen two positive Phase III outcomes, 2 FDA approvals and one progressing to approval since […]